bfri stock: Biofrontera, Inc. Overview

BFRI (Biofrontera, Inc.) — Stock overview

As of 2026-01-28, the term "bfri stock" refers to the NASDAQ-listed common shares of Biofrontera, Inc. (ticker: BFRI), a U.S.-incorporated micro-cap biopharmaceutical company focused on commercializing dermatology products. This article provides a practical, source-driven summary of the company, its core products (for example Ameluz and Xepi), stock listing details, financial and ownership signals, regulatory and clinical context, risks, and where to find official disclosures. Readers will leave with clear next steps for monitoring the bfri stock and links to authoritative information channels.

Quick reading note: the keyword "bfri stock" appears throughout this guide to help search and clarity; it is the primary ticker reference for Biofrontera, Inc. on NASDAQ.

Company background

Biofrontera, Inc. is the U.S.-listed entity associated with the Biofrontera group that develops and commercializes dermatology treatments. The firm’s operations center on prescription dermatology products and photodynamic therapy (PDT) devices. Historically, the business has roots in the German parent group Biofrontera AG; the U.S. company operates as the vehicle for U.S. commercialization and for accessing American capital markets.

As of the reporting date in this article, investor relations materials and exchange filings identify the company as a small public company with corporate offices in the United States and commercial activities focused on the U.S. dermatology market. For formal corporate history, founding dates, and entity structure, the company’s investor relations and SEC filings are the primary authoritative documents.

Business operations and products

Biofrontera’s commercial portfolio centers on a small number of dermatology products and complementary devices:

• Ameluz (aminolevulinic acid) — a topical photosensitizer used with the BF-RhodoLED device for photodynamic therapy to treat actinic keratosis and certain superficial skin lesions. Ameluz is distributed through prescription channels and administered in dermatology clinics as part of PDT protocols.

• Xepi (ozenoxacin) — a topical antibiotic indicated for the treatment of impetigo. Xepi provides a topical, non-systemic option for localized skin infections.

• BF-RhodoLED — a light device designed to activate Ameluz during photodynamic therapy procedures.

Commercial strategy historically emphasizes direct U.S. commercialization for its prescription products, plus selective licensing or distribution partnerships in other jurisdictions. The firm’s model relies on physician adoption, reimbursement pathways, and clinic-level use of PDT protocols where Ameluz plus BF-RhodoLED are prescribed together.

The company is categorized as a micro-cap commercial-stage biopharmaceutical business: revenue is generally generated from product sales rather than milestone-only biotech licensing, but scale is small relative to large-cap pharmaceutical companies.

Corporate governance and management

Biofrontera’s public disclosures name its board of directors and senior management team; these typically include a CEO, CFO, and heads of commercial and regulatory affairs. Management changes and board appointments are announced via company press releases and listed on the investor relations page.

As of 2026-01-28, investors should consult the company’s investor relations releases for the most recent executive biographies and any recent leadership transitions. Corporate governance materials, including the charters for audit and compensation committees, are also available through the investor relations portal and in SEC filings.

Stock listing and trading information

• Ticker symbol: BFRI
• Exchange: NASDAQ (U.S. national securities exchange)
• Trading hours: standard U.S. market hours (regular session), with pre-market and after-hours trading available subject to exchange and broker conventions.

Because the bfri stock is a micro-cap security, typical trading characteristics include lower liquidity versus larger-cap names, wider bid/ask spreads at times, and price volatility tied to relatively small share flows. Market-data pages (for example the NASDAQ quote, financial portals, and brokerage pages) commonly display delayed quotes; check the source to confirm whether data are real-time or delayed by 15 minutes or more.

Brokerage platforms and market-data providers show intraday price, volume, and level II data when available. If you plan to trade the bfri stock, consider platforms that offer reliable market data and execution; Bitget provides trading services and user tools that can be reviewed for equities access and account setup.

Financial summary and key metrics

As a micro-cap public company, Biofrontera’s financial profile will typically show the following features (consult current SEC filings and market-data pages for exact figures):

• Market capitalization: in the micro-cap range (commonly defined as under $300 million). Specific market-cap figures change daily with the share price and should be checked on the NASDAQ market-activity page or the company’s investor relations dashboard.

• Revenue trends: commercial revenues driven by product sales (Ameluz, Xepi) with year-over-year variability depending on sales execution, clinic adoption of PDT, and geographic distribution. Historically, revenues for micro-cap specialty dermatology companies may be in the low- to mid-double-digit millions on an annual basis, but current amounts should be verified in the latest Form 10-Q or Form 10-K.

• Profitability: many small specialty companies are modestly profitable or operate at a net loss while investing in commercialization and regulatory activities. Key metrics to watch include net income (loss), adjusted EBITDA, and operating cash flow.

• Balance sheet highlights: cash on hand, short-term investments, and any outstanding debt or credit facilities. Micro-cap firms often conduct capital raises; available cash and access to financing are material to operations.

• Per-share metrics and ratios: EPS, P/E (if positive earnings exist), price-to-book, and enterprise value measures. For the bfri stock, conventional ratios can swing widely due to low float and volatile pricing.

All numeric and ratio details change over time; for precise and current figures use the company’s latest SEC filings and real-time market-data pages noted in the References.

Historical price performance

The bfri stock has historically shown significant intraday and multi‑period volatility consistent with small‑cap healthcare companies. Key points investors monitor include:

• 52‑week high and low: these are visible on NASDAQ and financial portals and illustrate the recent trading range.
• Year-to-date (YTD) and 1‑year returns: frequently updated on market-data pages.
• Volume and volatility patterns: low average daily volume can amplify price moves when institutional or retail interest increases.
• Dilutive events: capital raises, secondary offerings, or issuance of shares in connection with corporate transactions can materially increase share count and influence price. Any such events are disclosed in SEC filings and press releases.

For a reliable historical price chart and exact high/low values, consult the Nasdaq market-activity page or your brokerage’s charting tools.

Ownership, shareholders and insider activity

Ownership characteristics for the bfri stock commonly include:

• Shares outstanding and float: the total number of issued shares and the portion available for public trading are listed in the company’s periodic filings and market-data services.
• Institutional holdings: some smaller institutions may hold positions; the degree of institutional concentration varies and is reported in filings and aggregated by financial data providers.
• Insider holdings and transactions: officers, directors, and significant shareholders must file insider purchase/sale notices with the SEC; these are public and provide transparency on insider activity.

As of the report date, review the latest Form 4 filings, the company’s proxy statement, and institutional ownership tables on market-data portals to understand concentration and recent insider trades.

Recent developments and corporate actions

Material recent events affecting the bfri stock typically include:

• Clinical or regulatory milestones for Ameluz, Xepi, or other pipeline items (trial starts, positive data, label changes). Company press releases and investor-relations documents announce these.
• FDA actions and patent developments that influence exclusivity or product marketability.
• Capital raises, debt financings, or registered direct offerings that change capitalization.
• Licensing deals, distribution agreements, or partnerships expanding geographic reach or enhancing commercialization.

As of 2026-01-28, investors should consult the company’s press release archive and SEC filings for the latest announced events. Company-issued press releases and the investor relations page are the primary sources for confirmed corporate actions; market portals and finance news outlets provide summarized coverage.

Regulatory, clinical and patent matters

Regulatory and clinical status is critical for a dermatology company where product approvals determine market access:

• FDA approvals/clearances: Ameluz and Xepi have U.S. regulatory histories that define indicated uses and permitted marketing claims. Any changes to approvals, labeling, or regulatory status will be reported in FDA notices and company filings.

• Clinical trials: ongoing or planned clinical studies are typically registered on public registries and described in company releases; trial outcomes materially affect product labeling, adoption, and commercial opportunity.

• Patent protection and exclusivity: patent filings and granted patents contribute to commercial defensibility. Check the FDA Orange Book entries (for U.S. approved drugs) and company patent disclosures for details on patent term and coverage.

Regulatory or patent setbacks can materially affect the bfri stock; conversely, favorable trial results or strengthened IP can support commercial value. Always refer to the company’s regulatory announcements and the FDA’s public databases for official status.

Risks and uncertainties

Key risk categories relevant to the bfri stock include:

• Liquidity and market risk: as a micro-cap, the stock can exhibit wide bid/ask spreads and sudden price moves on relatively small trade sizes.

• Clinical and regulatory risk: product approvals, label expansions, or safety findings can materially change revenue prospects.

• Commercialization and reimbursement risk: adoption by dermatologists, payer coverage, and reimbursement levels determine real-world revenue potential.

• Intellectual property risk: the scope, duration, and enforceability of patents affect competitive position.

• Financing and dilution risk: small biotech/dermatology firms may need to raise capital, which can dilute existing shareholders if equity is issued.

• Operational risk: supply-chain disruptions, manufacturing issues, or litigation can affect operations and market perception.

This section is illustrative and not exhaustive; refer to the company’s “Risk Factors” in the annual report and recent SEC filings for a detailed, legally vetted list of risks.

Investor relations and public filings

Primary places to find authoritative, up-to-date information for the bfri stock include:

• Company investor relations site: press releases, investor presentations, corporate governance documents, and contact information for the investor relations team.

• SEC filings: Form 10‑Q (quarterly), Form 10‑K (annual), Form 8‑K (current events), Form S‑1 or registration statements (if applicable), and insider Form 4 filings.

• NASDAQ market-activity page: real-time or delayed listing information, trading volume, and official exchange notices.

For verification and historical records, the SEC EDGAR database and the company’s investor relations materials should be the first stop. When cross-checking market data, note whether financial portals display delayed quotes.

Market coverage and analyst commentary

The bfri stock typically has limited analyst coverage compared with larger pharmaceutical companies. Financial portals (CNBC, SoFi, MSN Money, FXEmpire, and others) aggregate quotes, basic stats, and sometimes summary commentary. When using third‑party sources, be aware of potential discrepancies in delayed data, and prioritize official filings for material disclosures.

If you rely on analyst notes, verify the date and the analyst’s assumptions. For micro-cap companies, coverage can be sparse and forecasts more sensitive to small changes in revenue or trial outcomes.

See also

• Biofrontera AG (parent / related corporate entity)
• Ameluz (product overview and PDT usage)
• FDA Orange Book (U.S. drug patent and exclusivity listings)
• NASDAQ micro-cap listings and guidance

References

• Company investor relations and press releases (primary source for corporate disclosures and management comments)
• NASDAQ market-activity and quote page for BFRI (exchange listing, trading data and official notices)
• Financial portals and quote aggregators (CNBC, FXEmpire, Robinhood, SoFi, MSN Money, Markets.com, CNN Markets) for price snapshots, historical charts and aggregated key statistics
• GuruFocus for financial summaries, filings aggregation and metrics

As of 2026-01-28, these sources provide the basis for price and company context reported above; for any numeric figure or material corporate action referenced here, consult the original source documents on the company’s investor relations page and the SEC EDGAR database.

How to monitor bfri stock and next steps

For investors and observers who want to keep track of the bfri stock:

• Subscribe to company press releases via the investor relations page to receive timely company announcements.
• Check SEC filings (Form 10‑Q, 10‑K, 8‑K) for audited financials and material events.
• Use NASDAQ’s market-activity page and reputable financial portals for price and volume data; confirm whether data are real-time or delayed.
• Review patent and FDA databases for changes in regulatory status or patent listings affecting Ameluz and Xepi.
• When trading, consider execution quality, fees, and liquidity — platforms such as Bitget offer trading services and account tools that can help manage orders and access market data.

Reminder: this article is factual and informational only. It is not investment advice. Evaluate your objectives and consult licensed advisors before making investment decisions.

Additional practical notes for beginners

Beginners tracking the bfri stock should prioritize three simple routines:

1. Check the latest SEC filing after any material press release to confirm details and read management discussion.
2. Observe average daily volume and bid/ask spreads before placing orders; low-volume stocks can have poor execution on some platforms.
3. Track clinical and regulatory calendars for known milestones that could cause price movement.

For custody and account setup, Bitget’s platform and Bitget Wallet provide user onboarding resources and customer support options; explore platform features for market data, order types, and account security practices.

Final remarks and where to learn more

The bfri stock represents ownership in a specialized, micro-cap dermatology company with commercial products and ongoing regulatory attention. Price and fundamentals can change rapidly; rely on primary documents and exchange notices for material facts. To explore trading access and account services, consider Bitget’s platform solutions and Bitget Wallet for secure credential management.

Want to dig deeper? Start with the company’s latest annual report and the NASDAQ quote page for BFRI, then review recent investor presentations to understand management’s strategy and near-term milestones.

Explore more Bitget features to monitor markets, set alerts, and manage positions responsibly. Immediately review official filings for any time-sensitive corporate announcements affecting the bfri stock.